Celgene Corporation  

(Public, NASDAQ:CELG)   Watch this stock  
Find more results for CELG
104.10
+0.75 (0.73%)
Nov 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 103.24 - 104.59
52 week 94.55 - 147.17
Open 103.49
Vol / Avg. 5.97M/10.30M
Mkt cap 81.96B
P/E 24.53
Div/yield     -
EPS 4.24
Shares 787.32M
Beta 1.79
Inst. own 82%
Jan 24, 2018
Q4 2017 Celgene Corp Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 30, 2017
Celgene Corp at Evercore ISI Biopharma Catalyst/Deep Dive Conference - 11:00AM EST - Add to calendar
Nov 14, 2017
Celgene Corp at Stifel Healthcare Conference - Webcast
Nov 7, 2017
Celgene Corp at Credit Suisse Healthcare Conference - Webcast
Oct 28, 2017
Celgene Corp Investor Event at the MSParis2017-7th Joint American-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS/ ACTRIMS) - Webcast - Webcast
Oct 26, 2017
Q3 2017 Celgene Corp Earnings Release
Oct 26, 2017
Q3 2017 Celgene Corp Earnings Call - Webcast
Sep 26, 2017
Celgene Corp at Cantor Fitzgerald Global Healthcare Conference - Webcast
Sep 14, 2017
Celgene Corp at Bank of America Merrill Lynch Health Care Conference - Webcast
Sep 13, 2017
Celgene Corp at Morgan Stanley Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 30.06% 17.80%
Operating margin 32.98% 25.02%
EBITD margin - 33.76%
Return on average assets 12.77% 7.26%
Return on average equity 43.32% 31.94%
Employees 7,132 -
CDP Score - B

Address

86 Morris Ave
SUMMIT, NJ 07901-3915
United States - Map
+1-908-6739000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

Officers and directors

Robert J. Hugin Executive Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Scott A. Smith President, Chief Operating Officer
Age: 55
Bio & Compensation  - Reuters
Mark J. Alles Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Peter N. Kellogg Chief Financial Officer, Executive Vice President
Age: 61
Bio & Compensation  - Reuters
Terrie Curran President, Global Inflammation & Immunology Franchise
Age: 48
Bio & Compensation  - Reuters
Michael F. Pehl President, Hematology & Oncology
Age: 52
Bio & Compensation  - Reuters
Rupert J. Vessey President - Research and Early Development
Age: 52
Bio & Compensation  - Reuters
Gerald F. Masoudi Executive Vice President, General Counsel and Corporate Secretary
Age: 49
Bio & Compensation  - Reuters
Michael D. Casey Lead Independent Director
Age: 71
Bio & Compensation  - Reuters
Michael W. Bonney Director
Age: 58
Bio & Compensation  - Reuters